Minimally Invasive Neurosurgery Will Improve Global Clinical Outcomes

Published
29 Mar 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$29.00
63.8% undervalued intrinsic discount
15 Aug
US$10.50
Loading
1Y
-10.3%
7D
-6.4%

Author's Valuation

US$29.0

63.8% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 16%

Shared on24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 13%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 0.69%

Shared on02 Apr 25
Fair value Increased 26%

AnalystConsensusTarget has decreased revenue growth from 35.9% to 24.6%, increased future PE multiple from 76.6x to 125.7x and increased shares outstanding growth rate from 0.0% to 0.0%.